Show Navigation

Image 1 of 1

ALZHEIMER BLOOD 17.jpg

ST. LOUIS - Sept. 9, 2022: Dr. Randall J. Bateman, MD, a neurologist at Washington University in St. Louis and a co-founder of C2N Diagnostics, poses for a photograph at the company’s offices in St. Louis Friday, Sept. 9, 2022. The firm has is offering an in vitro diagnostic laboratory-developed test for brain amyloid detection, a pathologic hallmark of Alzheimer’s disease. (Photo by Sid Hastings/For The Washington Post)
Copyright
© Sid Hastings
Image Size
6000x4552 / 12.9MB
https://www.sidhastings.com/p/image-license-or-pur
https://www.sidhastings.com/contact
Contained in galleries
ST. LOUIS - Sept. 9, 2022: Dr. Randall J. Bateman, MD, a neurologist at Washington University in St. Louis and a co-founder of C2N Diagnostics, poses for a photograph at the company’s offices in St. Louis Friday, Sept. 9, 2022. The firm has is offering an in vitro diagnostic laboratory-developed test for brain amyloid detection, a pathologic hallmark of Alzheimer’s disease. (Photo by Sid Hastings/For The Washington Post)